INVO Fertility, Inc. (IVF) - Form 10-Q Summary
Business Context and Reporting Period
Company: INVO Fertility, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: INVO is a healthcare services and technology company focused on the fertility marketplace. Its strategy involves acquiring and operating fertility clinics and distributing its proprietary INVOcell device, which enables intravaginal culture (IVC). As of the filing date, the company operates four fertility clinics in the United States.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $2,175,485 | $4,190,710 |
| Net Income (Loss) | $888,740 | $(4,650,611) |
| Net Income (Loss) from Continuing Ops | $888,740 | $(4,650,611) |
| EPS (Basic) | $0.42 | $(2.48) |
| Cash and Cash Equivalents | $3,732,945 | $3,732,945 |
| Total Assets | $25,834,562 | $25,834,562 |
| Total Liabilities | $9,342,984 | $9,342,984 |
| Stockholders' Equity | $16,491,578 | $16,491,578 |
| Accumulated Deficit | $(96,035,618) | $(96,035,618) |
Segment Performance (Six Months Ended June 30, 2026):
- Fertility Clinic Services: Revenue of $4,150,018; Segment Profit of $429,455.
- INVOcell Distribution: Revenue of $40,692; Segment Loss of $(29,469).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 18% quarter-over-quarter (QoQ) and 20% year-over-year (YoY) for the six-month period. This growth is primarily attributed to the acquisition of the Family Beginnings clinic in Indiana and organic growth at existing clinics.
- Profitability Shift: The company reported a net income of $888,740 for the quarter ended June 30, 2026, compared to a net loss of $3.6 million for the same period in 2025. This improvement is largely driven by a $2.45 million gain on the remeasurement of a note receivable and equity interest related to the acquisition of HRCFG (Alabama JV).
- Discontinued Operations: The prior year period (2025) included significant losses from discontinued operations related to the divestiture of NAYA Therapeutics (NTI), totaling approximately $18.0 million for the six months ended June 30, 2025. No such losses were recorded in 2026.
- Impairment Losses: The company recorded no impairment loss in the current period, compared to $1.4 million in the prior year quarter related to a non-competition agreement settlement.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
Management plans to continue growing clinic revenue organically and pursuing additional profitable fertility clinic acquisitions. The company intends to use proceeds from recent financing to support expansion efforts. The focus remains on transforming from a medical device company to a healthcare services company with scale.
Going Concern Warning:
The filing explicitly states that the company's history of net operating losses and dependence on continued access to capital raise substantial doubt about its ability to continue as a going concern for at least one year from the date of the report. The company will need to raise additional funding to meet liquidity needs and execute its strategy.
Key Risks and Contingencies:
- Liquidity: Dependence on debt and equity financings which may not be available on reasonable terms.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to material weaknesses including limited segregation of duties and a lack of adequate accounting resources for complex transactions.
- Acquisition Integration: Risks associated with successfully completing and integrating fertility clinic acquisitions.
- Regulatory: Evolving state and federal laws on abortion and embryo personhood, and FDA clearance processes.
Recent Developments (Subsequent Events):
- Any Market Purchase Agreement (AMPA): Entered into an agreement with Alumni Capital LP to sell up to $15 million of common stock (potentially increasing to $50 million) to fund expansion.
- Stock Split & Authorization: Stockholders approved a reverse stock split (1-for-5) in March 2026 and an increase in authorized common stock to 250,000,000 shares in July 2026.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.7 million cash balance against the stated "substantial doubt" regarding going concern status and upcoming debt obligations.
- Debt Structure: Review the terms of the JAG Notes and Revenue Loan and Security Agreement (RSLA), specifically the high interest rates, conversion features, and maturity dates (e.g., JAG Notes extended to Dec 31, 2026).
- Internal Control Remediation: Assess the timeline and progress of remediation plans for the material weaknesses in internal controls over financial reporting.
- Acquisition Pipeline: Evaluate the feasibility of the stated strategy to acquire additional profitable clinics given current liquidity constraints.
- Warrant Liability: Confirm the impact of the reclassification of warrant liabilities to equity and the associated non-cash gains/losses on net income.